IMatinib for PAin in Chronic Treatment of Sickle Cell Anemia (IMPACT SCA): A Pilot Study of Imatinib in Patients with Sickle Cell Anemia and Recurrent Vaso-occlusive Pain
In this research study, we want to learn more about treatment of sickle cell anemia (SCA). Imatinib is a medication that is commonly used to treat certain types of cancers. Imatinib has not been approved to treat SCA or any pain associated with anemia and is considered an investigational treatment (i.e. not approved by the FDA) for this research study.
Participants who join as a normal donor for this study will be asked to provide blood samples up to 5 times in a 7-month period. This blood will be drawn from the arm using an IV needle. This needle will be removed after blood is collected.
Participants who receive treatment will come to Riley Hospital for Children Outpatient Center 7 times over the next 7 months and take an oral dose of imanitib every day for the next 6 months. Visits will include: review of medical history; physical exam with vital signs; height and weight measurement; EKG; echocardiogram; blood tests; review of study pain journal; urine pregnancy test (for women of childbearing potential).
Participants who are taking part in treatment will receive a $50 gift card for each monthly visit after the initial baseline visit.
- IRB Number: 1905035827
- Research Study Identifier: 1905035827
- Principal Investigator: Seethal Jacob, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required